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Figure 1. Outline of the synthesis of teixobactin analogues. 
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The archetypal prodrug of the imidazotetrazine class is the anticancer agent temozolomide 
(TMZ). The prodrug activation kinetics of TMZ show an unusual pH dependence: it is stable in acid 
and rapidly hydrolyses in alkali (Denny, B.J., et al. Biochemistry 1994, 33, 9045–9051). The incipient 
drug MTIC has the opposite properties—relatively stable in alkali but unstable in acid. In this study, 
the mechanism of prodrug activation was probed in greater detail to determine whether the reactions 
are specific or general acid or base catalysed. Three prodrugs and drugs were investigated, TMZ, 
MTIC and the novel dimeric imidazotetrazine EA27. Hydrolysis in a range of citrate-phosphate buffers 
(pH 8.0, 7.4, 4.0) was measured by UV spectrophotometry.  
 
Figure 1. EA27 (top), example hydrolysis data (L) and the prodrug activation mechanisms determined 
(R). 
Reaction of TMZ and MTIC obeyed single-phase, pseudo-first order kinetics (Figure 1). EA27 
was more complex, showing biphasic but approximately pseudo-first order kinetics, Figure. General 
acid or base catalysis indicates that protonation or deprotonation is the rate-limiting step (rls). In 
biological milieu, the nature and concentration of other acidic or basic solutes may affect the prodrug 
activation reaction. In contrast, specific acid or base catalysis indicates that protonation or 
deprotonation occurs before the rls, so catalysis depends only on the local concentration of hydroxide 
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Figure 1. EA27 (top), example hydrolysis data (L) and the prodrug activation mechanisms
determined (R).
The difference in reactivity between the tetrazines of the symmetrical dimer EA27 is surprising.
This suggests a sequential mechanism where the hydrolysis of one imidazotetrazine slows the
rate of the second within the same molecule, even though the two are FIVE atoms apart and not
conjugated. The switch of mechanism (especially at pH 8) between TMZ and EA27 implies a role for
the intramolecular secondary amine at the rate-limiting step.
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Silane-substituted imidazotetrazines 1,2 were investigated for their activity as anticancer prodrugs
related to temozolomide (TMZ). The TMS-derivative 1 showed an activity profile against TMZ
susceptible and resistant cell lines very similar to TMZ; in contrast, the SEM-derivative 2 showed
activity irrespective of MGMT expression or MMR deficiency (Table).
Probing the prodrug activation mechanism by NMR kinetic studies determined that the TMS
compound 1 follows a reaction pathway and time-course very similar to temozolomide. 1H-NMR
spectra of the reaction mixture showed considerable incorporation of deuterium into the final
alkylation products of the reaction (methanol and methyl phosphate) as had previously been shown
for temozolomide (Wheelhouse, R.T., et al. Chem. Commun. 1993, 15, 1177–1178). The SEM-derivative
2 reacted more rapidly than TMZ or TMS-derivative 1. Somewhat surprisingly, the silane remained
intact throughout the experiment and the observed reaction was the hydrolysis of the imidazo-tetrazine
to ultimately release formaldehyde hydrate and 2-TMS-ethanol.
In conclusion, TMS-derivative 1 is a diazomethane precursor with prodrug activation mechanism,
kinetics and anti-cancer activity in vitro similar to TMZ. In contrast, the SEM derivative 2 was more
rapidly hydrolysed, a precursor of 2-TMS-ethanol and had activity in vitro different from TMZ.
2-TMS-ethanol was previously reported as a non-toxic compound in mice (Voronkov, M.G., et al.
Dokl. Akad. Nauk SSSR 1976, 229, 1011–1013) and is known as a substrate for alcohol dehydrogenase
(Zong, M.-H., et al. Appl. Microbiol. Biotechnol. 1991, 36, 40–43) and as a modest inhibitor of
acetylcholinesterase (Aberman, A., et al. Biochim. Biophys. Acta 1984, 791, 278–280; Cohen, S.G., et al.
J. Med. Chem. 1985, 28, 1309–1313).
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or hydronium ion (i.e., pH) so the reaction kinetics are not expected to change appreciably in a 
biological medium. 
The difference in reactivity between the tetrazines of the symmetrical dimer EA27 is surprising. 
This suggests a sequential mechanism where the hydrolysis of one imidazotetrazine slows the rate of 
the second within the same molecule, even though the two are FIVE atoms apart and not conjugated. 
The switch of mechanism (especially at pH 8) between TMZ and EA27 implies a role for the 
intramolecular secondary amine at the rate-limiting step. 
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Silane-substituted imidazotetrazines 1,2 were investigated for their activity as anticancer 
prodrugs related to temozolomide (TMZ). The TMS-derivative 1 showed an activity profile against 
TMZ susceptible and resistant cell lines very similar to TMZ; in contrast, the SEM-derivative 2 
showed activity irrespective of MGMT expression or MMR deficiency (Table). 
Probing the prodrug activation mechanism by NMR kinetic studies determined that the TMS 
compound 1 follows a reaction pathway and time-course very similar to temozolomide. 1H-NMR 
spectra of the reaction mixture showed considerable incorporation of deuterium into the final 
alkylation products of the reaction (methanol and methyl phosphate) as had previously been shown 
for temozolomide (Wheelhouse, R.T., et al. Chem. Commun. 1993, 15, 1177–1178). The SEM-derivative 
2 reacted more rapidly than TMZ or TMS-derivative 1. Somewhat surprisingly, the silane remained 
intact throughout the experiment and the observed reaction was the hydrolysis of the imidazo-
tetrazine to ultimately release formaldehyde hydrate and 2-TMS-ethanol. 
 
Activity of TMZ, compounds 1 and 2 against a panel of TMZ susceptible and resistant cell lines 
Compound 
GI50 Value ± SD (µM) 
U373 V U373 M HCT 116 
TMZ 51.9 ± 7.4 302 ± 56 291 ± 4.9 
1 61.0 ± 6.0 >500 233 ± 80 
2 36.1 ± 2.9 29.1 ± 2.5 32.3 ± 10 
In conclusion, TMS-derivative 1 is a diazomethane precursor with prodrug activation mechan-
ism, kinetics and anti-cancer activity in vitro similar to TMZ. In contrast, the SEM derivative 2 was 
more rapidly hydrolysed, a precursor of 2-TMS-ethanol and had activity in vitro different from TMZ. 
2-TMS-ethanol was previously reported as a non-toxic compound in mice (Voronkov, M.G., et al. 
Dokl. Akad. Nauk SSSR 1976, 229, 1011–1013) and is known as a substrate for alcohol dehydrogenase 
(Zong, M.-H., et al. Appl. Microbiol. Biotechnol. 1991, 36, 40–43) and as a modest inhibitor of 
acetylcholinesterase (Aberman, A., et al. Biochim. Biophys. Acta 1984, 791, 278–280; Cohen, S.G., et al. 
J. Med. Chem. 1985, 28, 1309–1313). 
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6. Conclusions
The meeting was a success in its primary aims of bringing young researchers together to exchange
scientific ideas and experiences. New collaborations, formal and informal, were forged. Reflecting
the high standard of oral and poster presentations, prizes were awarded to young medicinal chemists.
Dr. Amit Nathubhai (University of Bath, Bath, UK) received the award for the best submitted oral
presentation, Isabelle Lengers (University of Münster, Münster, Germany) for the best poster with flash
oral presentation (sponsored by the Society of Chemical Industry Young Chemists Panel, London, UK).
Mike Kenny (University of Bath, Bath, UK) and Alexia Ville (Université d’Angers, Angers, France)
received awards for best posters (Sponsored by the Royal Society of Chemistry Liverpool Local Section,
Liverpool, UK).
The 26th Annual Meeting of GP2A is scheduled for 13–15 June 2018 in Asnelles-sur-Mer
(Normandie, France), as a joint meeting with the 32nd Journées Franco-Belges de Pharmacochimie.
With the election of a new President and new Committee for GP2A, the organisation looks
forward to developing and expanding its activities, fostering greater collaborations between member
laboratories and expanding into more countries in Western Europe.
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